Cassinelli Ezequiel H, Dean Clayton L, Garcia Ryan M, Furey Christopher G, Bohlman Henry H
Peachtree Orthopaedic Clinic, Atlanta, GA 30342, USA.
Spine (Phila Pa 1976). 2008 May 20;33(12):1313-7. doi: 10.1097/BRS.0b013e31817329bd.
Prospective randomized double-blind placebo-controlled study.
The objective of this study was to assess the efficacy of Ketorolac in reducing postoperative pain and morphine requirements following primary multilevel lumbar decompression surgery.
The use of opioid medications following surgical interventions can be complicated by related side effects such as respiratory depression, somnolence, urinary retention, and delayed time to oral intake. The use of Ketorolac, a potent nonopioid, nonsteroidal anti-inflammatory drug, is an attractive alternative to morphine as many of the opioid-related side effects can be avoided.
After Institutional Review Board approval, 25 patients who underwent a primary multilevel lumbar decompression procedure were randomly assigned to receive either Ketorolac or placebo in a double-blinded fashion. After surgery, all patients were allowed to receive intravenous morphine on an as needed basis. Morphine requirements were then recorded immediately postoperative, at 6, 12, and at 24 hours postoperative. A patient's overall hospital course morphine requirement was also assessed. Patient postoperative pain levels were determined using the Visual Analog Pain Scale and were documented at 4, 8, 12, 16, 24, and 36 hours postoperative.
There were no significant differences in available patient demographics, intraoperative blood loss, or postoperative Hemovac drain output between study groups. Morphine equivalent requirements were significantly less at all predetermined time points in addition to the overall hospital morphine requirement in patients randomized to receive Ketorolac. Visual Analog Pain Scores were significantly lower in patients randomized to receive Ketorolac immediately postoperative in addition to 4, 12, and 16 hours postoperative. There were no identifiable postoperative complications associated with the use of Ketorolac. CONCLUSION.: Intravenous Ketorolac seems to be a safe and effective analgesic agent following multilevel lumbar decompressive laminectomy. Patients can expect lower morphine requirements and better pain scores throughout their postoperative course.
前瞻性随机双盲安慰剂对照研究。
本研究的目的是评估酮咯酸在初次多节段腰椎减压手术后减轻术后疼痛及减少吗啡用量方面的疗效。
手术干预后使用阿片类药物会出现如呼吸抑制、嗜睡、尿潴留及口服摄入延迟等相关副作用。使用强效非阿片类非甾体抗炎药酮咯酸是一种有吸引力的替代吗啡的药物,因为可以避免许多与阿片类相关的副作用。
经机构审查委员会批准后,25例行初次多节段腰椎减压手术的患者以双盲方式随机分配接受酮咯酸或安慰剂治疗。术后,所有患者可根据需要接受静脉注射吗啡。记录术后即刻、术后6小时、12小时和24小时的吗啡用量。还评估了患者整个住院期间的吗啡总需求量。使用视觉模拟疼痛量表确定患者术后疼痛程度,并在术后4小时、8小时、12小时、16小时、24小时和36小时记录。
研究组之间在患者可用人口统计学资料、术中失血量或术后Hemovac引流液量方面无显著差异。随机接受酮咯酸治疗的患者在所有预定时间点以及整个住院期间的吗啡等效需求量均显著较低。随机接受酮咯酸治疗的患者在术后即刻以及术后4小时、12小时和16小时的视觉模拟疼痛评分显著较低。使用酮咯酸未发现可识别的术后并发症。
静脉注射酮咯酸似乎是多节段腰椎减压椎板切除术后一种安全有效的镇痛剂。患者在术后过程中可预期吗啡需求量降低且疼痛评分更佳。